HIV-1 Genotyping and Drug Resistance Test
Test Name: Human Immuno Virus 1 GENOTYPING and DRUG RESISTANCE Test
Components: 2 mL (1 mL min.) plasma from 1 Lavender Top (EDTA) tube
Price: 5030.0 AED
Sample Condition: Separate plasma within 6 hours of collection in a plastic transport vial and freeze immediately. Ship frozen. DO NOT THAW.
Report Delivery: Sample by 1st / 15th; Report on 15th / 30th of every month
Method: Reverse Transcriptase PCR and DNA Sequencing
Test Type: AIDS
Doctor: Physician
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information: No special preparation required
Test Details
Human Immunodeficiency Virus 1 (HIV-1) genotyping and drug resistance testing are important diagnostic tools used in the management of HIV-infected individuals. These tests help determine the genetic makeup of the virus and identify any mutations or resistance patterns that may affect the effectiveness of antiretroviral therapy (ART).
HIV-1 genotyping involves analyzing the genetic material (RNA) of the virus to determine its specific subtype and genetic variations. This information is essential for understanding the epidemiology and transmission of the virus, as well as for guiding treatment decisions. HIV-1 is classified into several subtypes, known as clades (A, B, C, etc.), and each subtype may have different response patterns to antiretroviral drugs.
Drug resistance testing aims to identify specific mutations in the viral genome that confer resistance to certain antiretroviral drugs. This testing is typically performed when a person is starting or changing their ART regimen or when their viral load is not suppressed despite adherence to treatment. By detecting drug resistance mutations, healthcare providers can choose the most appropriate antiretroviral drugs that will effectively suppress viral replication.
Both genotyping and drug resistance testing are usually performed using a blood sample. The viral RNA is extracted from the sample and amplified through a process called polymerase chain reaction (PCR). The amplified genetic material is then sequenced and analyzed to determine the viral subtype and any drug resistance mutations present.
The results of these tests are used by healthcare providers to tailor ART regimens to the individual’s specific viral genotype and drug resistance profile. This personalized approach helps maximize treatment effectiveness and minimize the development of drug resistance.
It is important to note that HIV-1 genotyping and drug resistance testing are typically performed in specialized laboratories and may not be available in all healthcare settings. Additionally, these tests are usually reserved for individuals with HIV infection who require treatment or have treatment failure.
| Test Name | Human Immuno Virus 1 GENOTYPING and DRUG RESISTANCE Test |
|---|---|
| Components | |
| Price | 5030.0 AED |
| Sample Condition | 2 mL (1 mL min.) plasma from 1 Lavender Top (EDTA) tube. Separate plasma within 6 hours of collection in a plastic transport vial and freeze immediately. Ship frozen. DO NOT THAW. |
| Report Delivery | Sample by 1st / 15th;Report on 15th / 30th of every month |
| Method | Reverse Transcriptase PCR and DNA Sequencing |
| Test type | AIDS |
| Doctor | Physician |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | No special preparation required |
| Test Details | Human Immunodeficiency Virus 1 (HIV-1) genotyping and drug resistance testing are important diagnostic tools used in the management of HIV-infected individuals. These tests help determine the genetic makeup of the virus and identify any mutations or resistance patterns that may affect the effectiveness of antiretroviral therapy (ART). HIV-1 genotyping involves analyzing the genetic material (RNA) of the virus to determine its specific subtype and genetic variations. This information is essential for understanding the epidemiology and transmission of the virus, as well as for guiding treatment decisions. HIV-1 is classified into several subtypes, known as clades (A, B, C, etc.), and each subtype may have different response patterns to antiretroviral drugs. Drug resistance testing, on the other hand, aims to identify specific mutations in the viral genome that confer resistance to certain antiretroviral drugs. This testing is typically performed when a person is starting or changing their ART regimen or when their viral load is not suppressed despite adherence to treatment. By detecting drug resistance mutations, healthcare providers can choose the most appropriate antiretroviral drugs that will effectively suppress viral replication. Both genotyping and drug resistance testing are usually performed using a blood sample. The viral RNA is extracted from the sample and amplified through a process called polymerase chain reaction (PCR). The amplified genetic material is then sequenced and analyzed to determine the viral subtype and any drug resistance mutations present. The results of these tests are used by healthcare providers to tailor ART regimens to the individual’s specific viral genotype and drug resistance profile. This personalized approach helps maximize treatment effectiveness and minimize the development of drug resistance. It is important to note that HIV-1 genotyping and drug resistance testing are typically performed in specialized laboratories and may not be available in all healthcare settings. Additionally, these tests are usually reserved for individuals with HIV infection who require treatment or have treatment failure. |
